Adult patients with advanced hematological malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have a poor prognosis because of high rate of relapse. For patients with recurrent disease, salvage chemotherapy or intensive conditioning followed by a second HSCT may be applied; however, aggressive chemotherapy for patients who relapse within 100 days after transplantation is associated with a high mortality and a low rate of complete remission. Even in case of late relapse, long-term survivors are few, although temporary complete remissions (CR) have been restored. Donor lymphocyte infusion (DLI) is regarded as one of the main therapeutic options for relapsed hematological malignancies after allo-HSCT. However, its effect has been confirmed only in early-stage of chronic myelogenous leukemia (CML) in contrast to advanced-stage of CML and other refractory hematological malignancies. Prophylactic DLI exhibited definite effect on the patients with highly aggressive hematological malignancies that had short doubling time. It is also known that DLI could be followed by high rate of severe graft-versus-host disease (GVHD), sometimes, pancytopenia and infection. 1 Many studies have demonstrated that in vivo granulocyte colony stimulating factor (G-CSF) could modify the function of lymphocytes in peripheral blood harvest.
Prophylactic infusion of donor granulocyte colony stimulating factor mobilized peripheral blood progenitor cells after allogeneic hematological stem cell transplantation in patients with high-risk leukemia Adult patients with advanced hematological malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have a poor prognosis because of high rate of relapse. For patients with recurrent disease, salvage chemotherapy or intensive conditioning followed by a second HSCT may be applied; however, aggressive chemotherapy for patients who relapse within 100 days after transplantation is associated with a high mortality and a low rate of complete remission. Even in case of late relapse, long-term survivors are few, although temporary complete remissions (CR) have been restored. Donor lymphocyte infusion (DLI) is regarded as one of the main therapeutic options for relapsed hematological malignancies after allo-HSCT. However, its effect has been confirmed only in early-stage of chronic myelogenous leukemia (CML) in contrast to advanced-stage of CML and other refractory hematological malignancies. Prophylactic DLI exhibited definite effect on the patients with highly aggressive hematological malignancies that had short doubling time. It is also known that DLI could be followed by high rate of severe graft-versus-host disease (GVHD), sometimes, pancytopenia and infection. 1 Many studies have demonstrated that in vivo granulocyte colony stimulating factor (G-CSF) could modify the function of lymphocytes in peripheral blood harvest. 2, 3 Recently, we reported that the infusion of donor G-CSF-mobilized peripheral blood progenitor cells (GPBPC) instead of donor lymphocytes showed a superantileukemic effect and this approach may accompany the decrease of infusion-related GVHD and rarely be complicated with pancytopenia. 4 So, we hypothesize that the prophylactic GPBPC infusion can induce antileukemic effect and lower the incidence of relapse with more safety. Here, we report the preliminary results from trials of allo-HSCT followed by planned prophylactic GPBPC infusion in patients with high-risk hematological malignancies.
From May 2001 to March 2004, 24 patients with hematological malignancies who had a high risk of relapse were allocated on an intend-to-treat basis to allo-HSCT followed by prophylactic GPBPC infusion. All the healthy donors and the recipients signed the consent form for stem cell collection and transplantation and stem cell cryopreservation for later prophylactic GPBPC infusion. Hematological malignancies with high risk of relapse were defined as acute leukemia in the first complete remission (CR1) with unfavorable cytogenetic abnormalities such as positive Ph chromosome, acute leukemia in more than CR1 status or in nonremission state, CML in accelerate phase (AP) and blast crisis (BC), myelodyplastic syndrome-refractory anemia with excess blast (MDS-RAEB) and primary refractory lymphoma. Among the 24 patients, seven were AML in nonremission state, one was in the third CR, five were ALL in nonremission state, three were Ph þ ALL in CR1 after Glivec therapy, six patients were CML in AP and BC, the other two patient were MDS-RAEB. All patients underwent HLA identical-sibling transplantation. The source of stem cells were G-CSF mobilized peripheral blood stem cells (PBSCs) for 13 patients and the mixture of G-CSF-mobilized bone marrow cells and PBSCs for the other 11 patients. The median age of the 24 HSCT recipients was 32 years (range, 12-64 years).
Patients older than 60 years old received nonmyeloablative conditioning, which consisted of arabinosylcytosine (Ara-C) 1 g/m 2 /day Â 1 day, cyclo-hosphamide (Cy) 1 g/m 2 /day Â 2 days, busulfan (Bu) 4 mg/kg/day Â 3 days, Simustine (Me-CCNU) 250 mg/kg/day Â 1 day and antithymoglobulin (porcine ATG, Wuhan, China) 20 mg/kg/day Â 4 days. All other patients received myeloablative conditioning, either total body irradiation and cyclophosphomide regimen (TBI/Cy), which consisted of TBI with 7.7 Gy and Cy 1.8/m 2 /day Â 2 days or the modified busulfan-cyclophosphamide regimen (mBuCy), which consisted Ara-C 2g/m 2 /day Â 1 day, Cy 1.8 g/m 2 /day Â 2 days, Bu 4 mg/kg/ day Â 3 days and Me-CCNU 250 mg/kg/day Â 1 day. Our data showed no difference between these two regimens on relapse. All patients received cyclosporine A (CsA), mycophenolate mofetile (MMF) and short-term methotrexate (MTX) to prevent GVHD. MTX was administered 15 mg/m 2 intravenously on day þ 1 and 10 mg/m 2 intravenously on days þ 3, þ 6, and þ 11. MMF was administered 0.5, q12 h, orally from day À9 to the day of engraftment. The dose of CsA was 2.5 mg/kg/day, administered intravenously from day À9 until the patient's bowel function was normal, then CsA was taken orally. The diagnosis and grading of GVHD was established according to published criteria. 5 White blood cells engraftment was defined as the number of days to achieve an Absolute Neutrophil Count (ANC) 40.5 Â 10 9 /l for three consecutive days. Platelet engraftment was defined as the time to achieve platelets 420 Â 10 9 /l without requiring blood transfusion.
Donors were mobilized with recombinant human G-CSF (rhG-CSF) (Filgrastim,Kirin, Japan) at 5 mg/kg daily injected subcutaneously for 5 consecutive days. Stem cells from bone marrow were collected on the forth day of mobilization and PBSCs on the fifth day in case of BMT combined with PBSCT. In case of PBSCT, PBSC was collected on the forth and the fifth day. Greater than 6 Â 10 8 mononuclear cells (MNC)/kg or 4 Â 10 6 CD 34 þ cells/kg were planned for harvest. The target numbers of cells of 44 Â 10 8 MNCs/kg or 2 Â 10 6 CD 34 þ cell/kg were planned for transplantation. Bone marrow was infused to patients within three hours after collection and PBSC product was infused fresh and unmanipulated. The extra harvested cells were cryopreserved with dimethyl sulfoxide in a nitrogen tank. Automated counter instrument was used to count MNCs. The numbers of CD 34 þ , CD 3 þ , CD 4 þ , CD 8 þ cells contained in the collected product were counted by flow cytometry. In case of ABO major blood group incompatibility, red cells in the marrow were removed by hydroxyethyl sediment manipulation.
Subsequent GPBPC administration was planned from day þ 45 to þ 120 in patients when no GVHD occurred even CsA was tapered or stopped; GVHD was controlled. Before GPBPC infusion, serious infection has to be cleared and no serious organ failure is present. For patients received GPBPC infusion before day þ 90, original CsA was continued for another 2 weeks after the infusion, then tapered and stopped within 4 weeks if no GPBPC infusion-associated GVHD occurred. For patients received GPBPC infusion after day þ 90, all immunosuppression agents should have been stopped for at least 2 weeks before the infusion and no active GVHD present. These patients took oral CsA for 2 weeks or MTX 10 mg once per week for 3 weeks after GPBPC infusion for the prevention of GPBPC infusion-associated GVHD. Chimerism status was compared before and after prophylactic GPBPC infusion, which was assessed by the variable number of tandem repeats (VNTR) in polymerase chain reaction (PCR) analysis or by chromosome examination. All patients achieved complete allogeneic engraftment as confirmed by VNTR study of chimerism status or by chromosome examination.
The median time to achieve WBC and platelet engraftment is 17.5 days and 18 days, respectively. Up to May 25th of 2005, eleven of the 24 patients were alive without disease recurrence. The median duration of recurrence free survival was 547 days (289-1286 days). Thirteen patients died of infection (n ¼ 1), pneumonitis (n ¼ 1) or recurrent disease (n ¼ 11). The KaplanMeier estimate of disease-free survival for all patients was shown in Figure 1 . Of the 24 patients, 12 (57.1%) received prophylactic GPBPC infusion after allo-HSCT. As shown in Table 1 , the prophylactic GPBPC infusion was administered between 43 and 314 days. A total 16 times of prophylactic infusion were performed. Nine patients received once, two patients received twice and one patient received three times of prophylactic infusion. The mononuclear cells (MNC) and CD3 Patient 2 and 9 received second prophylactic GPBPC infusion and patient 12 received three times. Patient 2 showed no signs of GVHD after the first prophylactic infusion and was diagnosed with chronic GVHD after the second prophylactic infusion and kept in disease-free survival after follow-up of 764 days. Patient 9 had limited chronic GVHD after the second prophylactic infusion and patient 12 never showed any signs of GVHD, they died of disease recurrence on day 410 and 80 after transplantation (300 days and 37 days after GPBSC infusion, respectively). Nine out of twelve patients who received prophylactic GPBPC infusion were free of relapse (1 year DFS 74%) when last accessed (median follow-up duration, 563 days; range, 289-764 days) and the other three died of disease recurrence. Six out of nine alive patients were still suffering from chronic GVHD (two patients had limited and the other four patients had extensive GVHD). All the nine survivors showed 100% donor chimerism in VNTR study before and after prophylactic GPBPC infusion. Prophylactic GPBPC infusion was not given in other 12 patients because of GVHD (n ¼ 4), disagreement (n ¼ 1) and relapse Comparison of probability of relapse. The probability of patients relapse was indicated along the transplantation time. Relapse of patients who received prophylactic GPBPC infusion was shown as broken line (---), whereas relapse of patients who did not receive any GPBPC was shown as real line.
Letters to the Editor (n ¼ 7). Eight of 12 patients who did not receive prophylactic GPBPC infusion relapsed between day 37 and day 120 after transplantation, then quit therapy and left hospital. One died of pneumonia on day 269 without disease recurrence. One suffered from extensive chronic GVHD and died of infection on day 736, when GVHD was already controlled. The other two patients who did not receive prophylactic infusion were alive without recurrence when last assessed on day 930 and day 1286.
Large clinical studies showed the allogeneic T cells can react against residual malignant cells, which may be enhanced by additional infusion of donor cells. 6 These results suggest that the direction of strategy against disease recurrence may convert from therapeutic DLI to prophylactic DLI for those with advanced hematological malignancies. The main obstacle for application of prophylactic DLI is the infusion-associated GVHD, pancytopenia and consequently, infection. It has been shown that G-CSF affects the cellular components of progenitor cells at harvest and modifies the function of T cells. Hence, we proposed that prophylactic infusion of G-CSF mobilized donor progenitor cells might be safer than infusion of nonprimed donor lymphocytes from view of infusion-associated complications. In addition, it was also showed by others and our own previous studies that the use of GPBPC was comparable to or even better than that of DLI from view of GVL effect. Patients received prophylactic GPBPC infusion did not show profound pancytopenia. Based on the results mentioned above, we started this pilot study to cryopreserve GPBPC at harvest and prepared to infuse them to prevent relapse after transplantation for the patients with high-risk hematologic malignancies. Of 21 patients, 12 received prophylactic GPBPC infusion and nine patients survived without recurrence after follow-up of median 563 days. No profound, lasting pancytopenia was observed, this was in accordance with Sohn Sk' observation. 7 In the current trial, acute GVHD occurred in five of 16 times of infusions, which were all controlled easily without GVHD related death, of which the reason is illustrated as followed. First, G-CSFmobilized donor lymphocytes may play an important role in mitigating infusion-induced GVHD. It has been postulated that type 1 cytokines, including IL-2 and IFN-g, could promote acute GVHD, whereas type 2 cytokines, including IL-4 and IL-10, help to suppress GVHD. The effect of in vivo G-CSF application on T-cell function has been extensively explored. Several reports and our preliminary data indicated the in vivo G-CSF application indirectly induced a decrease in T-cell proliferation and the type II helper T-cell polarization in the cytokine profile. Furthermore, T-cell hyporesponsiveness in bone marrow allo-grafts induced by in vivo G-CSF maybe related to the selective decrease of DC1 and the downregulation of CD28/B7 costimulatory signals. This may contribute to the antigen-specific hyporesponsiveness of T cell in G-CSF-mobilized harvest. The second reason may be the use of CsA or MTX for prevention of potential GVHD. It is known that abrupt withdrawal of immunosuppressive agents has been very risky because of the difficulty to control severe GVHD. Hence, we used CsA or MTX for a short period in the current study to prevent the infusion-induced GVHD. Experimental studies will be needed to clarify if sever GVHD related to prophylactic DLI could be mostly relieved by short time period of immunosuppression.
There are still several questions need to be answered for application of prophylactic GPBPC infusion. One of the questions is what is the appropriate time point to start prophylactic GPBPC infusion? In the early part of our study, most additional GPBPC were infused 90 days after transplantation due to worry about infusion-related GVHD. However, we observed some patients relapsed soon after engraftment and those patients who received prophylactic GPBPC infusion rarely had uncontrollable infusion associated GVHD or infection. Consequently, we promote the time point earlier, even to 6 weeks after transplantation for those patients with high blast count before transplantation. The time point to start strategy to prevent relapse could be determined by follow up of chimerism status, which may find mixed chimerism before overt disease recurrence. It has been studied to use quantitative analysis of hematopoietic chimerism status to predict the recurrence of disease. For instance, increasing mixed chimerism can be an indicator to start prophylactic DLI for the patients with high-risk leukemia. However, some patients with high-risk leukemia relapsed after allo-HSCT with full-donor chimerism, which is also observed in our current study. Then is it the earlier the better to perform the prophylactic infusion after allo-HSCT in patients with advanced leukemia? Or should the prophylactic infusion-related GVHD be thoroughly controlled by immunosuppressive agents as soon as possible? Serial experimental and clinical studies are needed to clarify these issues.
In conclusions, allo-HSCT with prophylactic GPBPC infusion could be a potentially safe and effective strategy to prevent relapse of hematological malignancies in patients with high risk of recurrence. Letters to the Editor
